Management of Postnasal Drip in Dialysis Patients

Medication Considerations

First-generation antihistamines, such as diphenhydramine and chlorpheniramine, are contraindicated in elderly patients with Alzheimer's disease due to strong anticholinergic effects that can worsen cognitive function, increase the risk of urinary retention, confusion, and falls, and precipitate delirium 1
Oral decongestants, such as pseudoephedrine and phenylephrine, should be avoided in patients with hypertension as they can significantly elevate blood pressure, trigger or worsen atrial fibrillation, and increase cardiovascular risks in elderly patients with existing cardiac disease 1
Second-generation antihistamines, such as cetirizine, loratadine, and fexofenadine, may be considered cautiously in elderly patients with cognitive impairment, but require careful dose adjustment in renal failure, with cetirizine and fexofenadine needing reduced dosing, while loratadine does not require adjustment 1
Intranasal ipratropium bromide can be added for profuse watery rhinorrhea, but should be used with extreme caution in patients with Alzheimer's disease, and avoided in those with glaucoma or significant prostatic hypertrophy 1

ACE inhibitors can trigger cough in dialysis patients by competing for ACE binding sites in the lungs, and consideration should be given to switching to an ARB if the patient is on an ACE inhibitor 2
Beta-blockers may exacerbate respiratory symptoms by triggering bronchoconstriction in dialysis patients 2
Gastroesophageal reflux is significantly more common in dialysis patients and may present as a postnasal drip sensation, and should be assessed for in these patients 2
Fluid overload and pulmonary edema must be excluded in dialysis patients presenting with cough or postnasal drip, and consideration should be given to tuberculosis screening due to relative immunosuppression in these patients 2

Patients started on systemic antihistamines should be monitored for any worsening of cognitive function 1

Intranasal corticosteroids (e.g., fluticasone, mometasone) provide the most effective long‑term relief of nasal congestion in elderly patients receiving dialysis, with negligible systemic absorption and therefore a favorable safety profile in this population. 3
Once‑daily dosing of intranasal corticosteroids is sufficient to achieve therapeutic effect and is readily available over‑the‑counter in most developed countries, simplifying adherence for older adults on dialysis. 3
Clinical improvement in nasal congestion typically becomes evident within a few days after initiating intranasal corticosteroid therapy, allowing rapid symptom control without systemic side effects. 3